Clinical Leadership Team
Andrew Norden, MD, MPH, MBA
Chief Medical Officer
As Chief Medical Officer, Dr. Norden leads Oncology Analytics’ clinical team and strategy. An accomplished neuro-oncologist, Dr. Norden previously served as Chief Medical Officer of COTA, an oncology company focused on the curation and use of real-world data and evidence for cancer care and research. Before COTA, Dr. Norden served as Deputy Chief Health Officer and lead physician for oncology and genomics at IBM Watson Health.
Before moving to IBM, Dr. Norden held several positions at the Dana-Farber Cancer Institute in Boston, including Associate Chief Medical Officer and Medical Director of Satellites and Network Affiliates. During his time at Dana Farber, Dr. Norden led clinical trials for patients with glioma, meningioma, and seizures in brain tumor patients. He is the author of more than 65 peer-reviewed papers. He is an active member of the American Society of Clinical Oncology and the Society for Neuro-Oncology, and he is an Associate Editor of JCO-Clinical Cancer Informatics.
Dr. Norden attended medical school at Yale School of Medicine before moving to Boston for residency training at Massachusetts General and Brigham and Women’s Hospitals. After serving as Chief Resident, he completed a neuro-oncology fellowship at Dana-Farber. Dr. Norden also earned a Masters of Public Health degree from the Harvard University School of Public Health and an MBA from the University of Massachusetts, Amherst. He received his undergraduate degree in neuroscience from Brown University.
Richard Wilder, MD, MBA
Senior Medical Director, Radiation Oncology
Dr. Wilder obtained an MD degree from the University of Maryland and an MBA degree from Johns Hopkins University. He completed an internal medicine internship at the Greater Baltimore Medical Center, a radiation oncology residency at the University of Arizona, and an ASTRO research fellowship at the Stanford University Medical Center. Dr. Wilder is board-certified in radiation oncology. He has worked on the faculty of leading academic centers such as the University of California, San Francisco and the MD Anderson Cancer Center.
Recently, Dr. Wilder served for 2 1/2 years as interim chair of the Department of Radiation Oncology at the Moffitt Cancer Center. During this time, he worked on radiation oncology treatment guidelines. Also, he served for five years as a Kidney and Testicular Cancer Panel Member for the NCCN, helping to write national evidence-based treatment guidelines. In addition, since 2002 he has served nationally as an oral board examiner for the American Board of Radiology. Dr. Wilder joined Oncology Analytics in 2016 as its Chief Medical Officer.
Laura R. Bobolts, PharmD, BCOP
Senior Vice President, Pharmacy
Dr. Bobolts is a board-certified Oncology Pharmacist that serves as an oncology medical information resource for Oncology Analytics, responsible for providing recommendations for alternative therapy or support for existing anti-cancer treatment plans based on evidence-based medicine. She manages a team of oncology pharmacists, provides recommendations for oncology-related national drug policies, and performs population-based research.
She is a graduate of Nova Southeastern University’s College of Pharmacy and completed a Pharmacy Practice Residency at the James A. Haley Veterans’ Hospital. She began her career at Moffitt Cancer Center, first specializing in malignant hematology and later specializing in breast and gynecologic oncology where she established the role of a clinical oncology pharmacist in the Women’s Oncology Clinic at Moffitt Cancer Center — consulting with attending oncologists and devising treatment plans directly from the outpatient clinic.
She is a Clinical Affiliate Assistant Professor for Nova Southeastern University’s College of Pharmacy, lecturing on various topics such as oncology pharmacy therapeutics and pediatric leukemias, upon request. She developed an APPE (Advanced Pharmacy Practice Experience) at Oncology Analytics, to teach pharmacy students more about the practice of oncology pharmacy benefits management. She is published in Lancet Oncology, a peer reviewer for JAMA Oncology and Clinical Genitourinary Cancer, as well as an oncology pharmacy topic writer for www.idstewardship.com. Her main area of research interest is invasive breast cancer.
Anna Schorer, MD
Medical Director, CMIO
Dr. Schorer focuses on clinical informatics and data management capabilities supporting our commitment to the delivery of safe, high-quality and cost-effective care for cancer patients. Prior to joining Oncology Analytics, Dr. Schorer was a clinician, educator and researcher in hematology and medical oncology at the Minneapolis VA Health Care System for more than two decades. In this position, she was a nationally known innovator in the design and optimization of electronic health systems and clinical decision support.
She conducted key health care improvement initiatives funded through the National Center for Patient Safety, the VA Office of Specialty Care Transformation, and the Midwest Health Care Network. Her project teams won awards for improving patient safety and care processes at the local, regional and national level. She also held a number of leadership roles within the Veterans Health Administration.
Dr. Schorer received her MD degree and did her Internal Medicine Residency at the University of Minnesota. She completed a Hematology/Medical Oncology Fellowship at the University of Washington and the University of Minnesota. She is board-certified in hematology, medical oncology, and clinical informatics, in addition to holding a Certificate in Clinical Informatics from the American Medical Informatics Association.